ACE Inhibitors Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Type (Sulfhydryl-containing Agents, Dicarboxylate-containing Agents, Phosphonate-containing Agents), By Drug (Ramipril, Enalapril, Benazepril, Fosinopril, Captopril, Moexipril, Others), By Dosage Form (Oral Tablets, Oral Solutions), By Application (Heart Failure, Chronic Kidney Disease, Hypertension, Diabetes, Heart Attack, Others), By End user (Hospitals, Online Drug Stores, Others), By Region and Competition, 2020-2030F

Market Overview

The Global ACE Inhibitors Market, valued at USD 6.94 Billion in 2024, is projected to experience a CAGR of 5.75% to reach USD 9.71 Billion by 2030. Angiotensin-converting enzyme (ACE) inhibitors constitute a class of pharmaceutical agents primarily utilized to relax blood vessels and reduce blood pressure, thereby managing conditions such as hypertension, heart failure, and chronic kidney disease. The market for these inhibitors is principally driven by the rising global prevalence of cardiovascular diseases and hypertension, alongside an expanding aging population. Furthermore, increasing public awareness regarding chronic disease management and continuous advancements in pharmaceutical research contribute significantly to market expansion. According to the World Health Organization, an estimated 1.4 billion adults aged 30–79 years worldwide had hypertension in 2024, underscoring a substantial patient base for ACE inhibitor therapies.

However, the market faces a significant impediment due to the potential for adverse effects associated with ACE inhibitors, including persistent cough, hyperkalemia, and rare angioedema, which can lead to patient non-adherence or discontinuation of therapy. Additionally, competition from alternative therapeutic classes, such as angiotensin II receptor blockers, presents a challenge to market share maintenance.

Key Market Drivers

The increasing global burden of cardiovascular diseases represents a fundamental driver for the ACE inhibitors market. The widespread prevalence of conditions such as hypertension and heart failure necessitates effective and accessible therapeutic options. These illnesses not only reduce quality of life but also place substantial strain on healthcare systems worldwide. According to the "Global, regional, and national burden of cardiovascular diseases and risk factors in 204 countries and territories, 1990-2023" published in JACC, in September 2025, the number of prevalent cases of cardiovascular disease reached 626 million globally in 2023, underscoring the vast and growing patient population requiring management for these conditions. This elevated disease burden directly fuels the demand for ACE inhibitors, which are cornerstone treatments for various cardiovascular ailments, driving sustained market expansion.

Compounding this effect is the expanding geriatric population base, a demographic particularly susceptible to cardiovascular conditions. As global life expectancies increase, the number of older adults requiring long-term management for chronic diseases like hypertension rises proportionally. This demographic shift leads to a greater prescription volume for cardiovascular medications. According to the CDC, in October 2024, the prevalence of hypertension in adults aged 60 and older was 71.6% during August 2021–August 2023, illustrating the high incidence of a key target condition for ACE inhibitors within this expanding age group. This trend reinforces the essential role of ACE inhibitors in geriatric care and contributes significantly to market growth. Furthermore, the pharmaceutical industry continues to invest in the hypertension drug sector, reflecting the ongoing market potential. According to pharmaphorum, in October 2025, AstraZeneca initiated the first stage of a $4.5 billion investment for a new facility in Virginia, which will produce various medicines including baxdrostat for high blood pressure.

Download Free Sample Report

Key Market Challenges

The potential for adverse effects associated with angiotensin-converting enzyme (ACE) inhibitors presents a significant impediment to market expansion. These side effects, including persistent cough, hyperkalemia, and rare angioedema, frequently lead to patient non-adherence or complete discontinuation of therapy. Such reactions directly diminish the patient base that continues to utilize ACE inhibitor treatments. According to research published in *Frontiers in Cardiovascular Medicine* in 2023, approximately 23.0% of patients prescribed ACE inhibitors were non-persistent with their treatment. This substantial rate of non-persistence, often influenced by the challenges of managing adverse drug reactions, directly limits the therapeutic lifespan of ACE inhibitors for individual patients. Consequently, this reduces the overall addressable market size and restricts the potential for sustained revenue generation, despite the increasing global prevalence of cardiovascular conditions requiring such interventions. The necessity for patients to modify or abandon ACE inhibitor regimens due to intolerance therefore directly hampers the expansion of the global ACE inhibitors market.

Key Market Trends

The growing adoption of fixed-dose combination therapies represents a pivotal trend in the Global ACE Inhibitors Market. These single-pill combinations enhance patient adherence by simplifying complex treatment regimens, which is crucial for managing chronic conditions like hypertension and heart failure. Such formulations improve therapeutic outcomes by ensuring consistent medication intake. For instance, according to a study published in *J Clin Hypertens (Greenwich)* in August 2025, patients receiving angiotensin-converting enzyme inhibitor or angiotensin receptor blocker combination therapies exhibited the highest adherence rate at 79.18% in 2022–2023, compared to other antihypertensive drug classes. This improvement in adherence directly contributes to better disease control and sustained demand for ACE inhibitor-inclusive fixed-dose combinations.

The proliferation of generic ACE inhibitor formulations also significantly shapes the market landscape. The expiry of patents for several branded ACE inhibitors has paved the way for more affordable generic alternatives, increasing accessibility for a broader patient population. This trend is particularly impactful in healthcare systems striving for cost-efficiency. A notable example of this trend is Pharmascience Inc. 's launch of pms-PERINDOPRIL-INDAPAMIDE in August 2023, a generic fixed-dose combination incorporating an ACE inhibitor for essential hypertension treatment in adults. The widespread availability of these cost-effective options fuels market expansion by making essential cardiovascular care more attainable across various economic segments.

Segmental Insights

Oral tablets is currently a fastest growing segment in the market due to factors such as ease of use and affordability. This growth in oral solutions is further attributed to increasing demand from pediatric and geriatric populations requiring easy-to-swallow or adjustable formulations, enhancing patient compliance and facilitating precise dosing, often preferred in hospital and long-term care settings.

Regional Insights

North America holds a leading position in the global ACE Inhibitors market, primarily driven by the substantial prevalence of cardiovascular diseases, particularly hypertension, across the region. This dominance is underpinned by a robust healthcare infrastructure providing advanced treatment facilities and widespread access to medical care. A key factor is the supportive regulatory environment, where institutions such as the U. S. Food and Drug Administration (FDA) facilitate the approval and market entry of effective therapeutic options. Furthermore, increasing awareness regarding cardiovascular health and improved diagnostic capabilities contribute significantly to early disease identification and subsequent demand for ACE inhibitors.

Recent Developments

• In October 2025, preliminary research, involving a novel medication developed by AstraZeneca, baxdrostat, was presented at the American Heart Association's Hypertension Scientific Sessions. The findings indicated that adding baxdrostat to existing standard care could effectively manage high blood pressure and slow the progression of kidney disease in patients with chronic kidney disease and uncontrolled hypertension. Many study participants were already receiving ACE inhibitors, highlighting the potential for new adjunctive therapies to work synergistically with established ACE inhibitor regimens, thereby impacting treatment strategies in the global ACE inhibitors market.

• In August 2025, Roche and Alnylam announced their decision to initiate a Phase III cardiovascular outcomes trial for zilebesiran, a novel RNAi therapeutic designed for hypertension treatment. This advancement was supported by comprehensive Phase II data, including the KARDIA-3 study, which demonstrated encouraging safety when zilebesiran was administered alongside existing antihypertensive medications, including ACE inhibitors. This development is significant for the global ACE inhibitors market as it highlights the continued relevance and potential for combination therapies that integrate new mechanisms with established ACE inhibitor treatments to improve patient care.

• In March 2025, Otsuka Pharmaceutical Co., Ltd. submitted a Biologics License Application for sibeprenlimab, an investigational treatment targeting Immunoglobulin A nephropathy. This regulatory filing was based on positive outcomes from the VISIONARY study, where standard-of-care therapy, which included maximally tolerated ACE inhibitors or Angiotensin Receptor Blockers, served as a foundational treatment. This initiative by Otsuka underscores the enduring role of ACE inhibitors as a critical component of baseline therapy in managing complex kidney conditions, demonstrating their established efficacy within evolving treatment landscapes in the global pharmaceutical market.

• In November 2024, late-breaking science presented at the American Heart Association's Scientific Sessions detailed a study on two-medication combination pills for blood pressure reduction. The TOPSPIN trial evaluated combinations including perindopril, an ACE inhibitor, with amlodipine or indapamide, concluding that all tested variations were equally effective and safe in lowering blood pressure among adults in India. These research findings are important for pharmaceutical companies, as they provide data that can influence the formulation and marketing of fixed-dose combination therapies incorporating ACE inhibitors for hypertension management in various global regions.

Key Market Players

• Pfizer Inc
• Novartis AG
• Johnson & Johnson
• Merck KGaA
• Sanofi S.A
• Bayer AG
• United Therapeutics Corporation
• Teva Pharmaceutical Industry
• Bristol-Myers Squibb
• Takeda Pharmaceuticals Company

Report Scope:

In this report, the Global ACE Inhibitors Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

• ACE Inhibitors Market, By Type:

o   Sulfhydryl-containing Agents

o   Dicarboxylate-containing Agents.

o   Phosphonate-containing Agents

• ACE Inhibitors Market, By Drug:

o   Ramipril

o   Enalapril

o   Benazepril

o   Fosinopril

o   Captopril

o   Moexipril

o   Others

• ACE Inhibitors Market, By Dosage Form:

o   Oral Tablets

o   Oral Solutions

• ACE Inhibitors Market, By Application:

o   Heart Failure

o   Chronic Kidney Disease

o   Hypertension

o   Diabetes

o   Heart Attack

o   Others

• ACE Inhibitors Market, By End user:

o   Hospitals

o   Online Drug Stores

o   Others

• ACE Inhibitors Market, By Region:

o   North America

§  United States

§  Canada

§  Mexico

o   Europe

§  France

§  United Kingdom

§  Italy

§  Germany

§  Spain

o   Asia Pacific

§  China

§  India

§  Japan

§  Australia

§  South Korea

o   South America

§  Brazil

§  Argentina

§  Colombia

o   Middle East & Africa

§  South Africa

§  Saudi Arabia

§  UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies presents in the Global ACE Inhibitors Market.

Available Customizations:

Global ACE Inhibitors Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

• Detailed analysis and profiling of additional market players (up to five).

Global ACE Inhibitors Market is an upcoming report to be released soon. If you wish an early delivery of this report or want to confirm the date of release, please contact us at [email protected]